November 8, 2016 / 12:42 PM / in a year

BRIEF-Orexigen signs commercialization, distributorship agreement with Valeant for Vontrave in Australia, New Zealand

Nov 8 (Reuters) - Orexigen Therapeutics Inc :

* Orexigen Therapeutics Inc - Orexigen expects Valeant to file for regulatory approvals in both countries in first half of 2017

* Valeant Pharma through a wholly owned subsidiary, will commercialize Contrave in Australia and New Zealand

* Orexigen Therapeutics - Orexigen will supply Contrave tablets to Valeant for an agreed transfer price and certain potential sales milestone payments

* Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant for Vontrave (naltrexone HCL/bupropion HCL extended release) in Australia and New Zealand Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below